Jones Alun, Dhamrait Sukhbir S, Payne John R, Hawe Emma, Li Ping, Toor Iqbal S, Luong Le, Wootton Peter T E, Miller George J, Humphries Steve E, Montgomery Hugh E
Centre for Cardiovascular Genetics, Royal Free and University College Medical School, London, UK.
Hypertension. 2003 Oct;42(4):500-6. doi: 10.1161/01.HYP.0000088853.27673.D0. Epub 2003 Aug 18.
Renin-angiotensin systems may mediate cardiovascular disease pathogenesis through a balance of actions of angiotensin II on (potentially proatherogenic) constitutive type 1 (AT1R) and (potentially antiatherogenic) inducible type 2 (AT2R) receptors. We explored such potential roles in a prospective candidate gene association study. Cardiovascular end points (fatal, nonfatal, and silent myocardial infarction and coronary artery bypass surgery/angioplasty) were documented among 2579 healthy UK men (mean age, 56.1+/-3.5 years; median follow-up, 10.1 years) genotyped for the AT1R1166A>C and the X chromosome located AT2R1675A>G and 3123C>A polymorphisms. Baseline characteristics, including blood pressure, were independent of genotype. The AT1R1166CC genotype was associated with relative cardiovascular risk (hazard ratio, 1.65 [1.05 to 2.59]; P=0.03) independent of blood pressure. Systolic blood pressure was associated with risk (P=0.0005), but this association was restricted to AT2R1675A allele carriers (P<0.00001), with G allele carriers protected from the risk associated with blood pressure (P=0.18). Hypertensive carriers with the AT2R1675A/3123A haplotype were at most risk, with 37.5% having an event. This is the first study to demonstrate an association of AT2R genotype with coronary risk, an effect that was confined to hypertensive subjects and supports the concept that the inducible AT2R is protective. Conversely, the AT1R1166CC genotype was associated with cardiovascular risk irrespective of blood pressure. These data are important to our understanding of the divergent role of angiotensin II acting at its receptor subtypes and coronary disease pathogenesis and for the development of future cardiovascular therapies.
肾素-血管紧张素系统可能通过血管紧张素II对(潜在促动脉粥样硬化的)组成型1型(AT1R)和(潜在抗动脉粥样硬化的)诱导型2型(AT2R)受体的作用平衡来介导心血管疾病的发病机制。我们在一项前瞻性候选基因关联研究中探讨了此类潜在作用。在2579名健康英国男性(平均年龄56.1±3.5岁;中位随访时间10.1年)中记录了心血管终点事件(致命性、非致命性和无症状心肌梗死以及冠状动脉搭桥手术/血管成形术),这些男性针对AT1R1166A>C以及位于X染色体上的AT2R1675A>G和3123C>A多态性进行了基因分型。包括血压在内的基线特征与基因型无关。AT1R1166CC基因型与相对心血管风险相关(风险比,1.65[1.05至2.59];P = 0.03),与血压无关。收缩压与风险相关(P = 0.0005),但这种关联仅限于AT2R1675A等位基因携带者(P<0.00001),G等位基因携带者可免受与血压相关的风险(P = 0.18)。具有AT2R1675A/3123A单倍型的高血压携带者风险最高,37.5%发生了事件。这是第一项证明AT2R基因型与冠心病风险相关的研究,该效应仅限于高血压受试者,并支持诱导型AT2R具有保护作用的概念。相反,无论血压如何,AT1R1166CC基因型都与心血管风险相关。这些数据对于我们理解血管紧张素II作用于其受体亚型的不同作用以及冠心病发病机制,以及未来心血管治疗的发展具有重要意义。